Dechra Pharmaceuticals plc (LON:DPH) insider Tony Griffin sold 17,133 shares of the company’s stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of GBX 1,292 ($16.03), for a total transaction of £221,358.36 ($274,604.09).

Shares of Dechra Pharmaceuticals plc (LON:DPH) traded up 0.16% during midday trading on Wednesday, hitting GBX 1274.00. 231,305 shares of the stock were exchanged. The firm’s 50 day moving average is GBX 1,326.89 and its 200-day moving average is GBX 1,267.41. The stock’s market capitalization is GBX 1.18 billion. Dechra Pharmaceuticals plc has a 1-year low of GBX 811.00 and a 1-year high of GBX 1,462.00.

The business also recently declared a dividend, which was paid on Friday, November 18th. Shareholders of record on Thursday, October 27th were issued a GBX 12.91 ($0.16) dividend. This represents a yield of 0.92%. This is a boost from Dechra Pharmaceuticals plc’s previous dividend of $5.55. The ex-dividend date of this dividend was Thursday, October 27th.

COPYRIGHT VIOLATION WARNING: “Dechra Pharmaceuticals plc (DPH) Insider Tony Griffin Sells 17,133 Shares” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/dechra-pharmaceuticals-plc-dph-insider-tony-griffin-sells-17133-shares.html.

A number of equities analysts recently weighed in on the stock. FinnCap reaffirmed an “under review” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. Numis Securities Ltd reaffirmed an “add” rating and issued a GBX 1,520 ($18.86) target price on shares of Dechra Pharmaceuticals plc in a research note on Thursday, October 27th. N+1 Singer boosted their price target on shares of Dechra Pharmaceuticals plc from GBX 1,350 ($16.75) to GBX 1,412 ($17.52) and gave the stock a “buy” rating in a research report on Friday, October 21st. Stifel Nicolaus reissued a “hold” rating and set a GBX 1,250 ($15.51) price target on shares of Dechra Pharmaceuticals plc in a research report on Friday, October 21st. Finally, Panmure Gordon reissued a “buy” rating and set a GBX 1,140 ($14.14) price target on shares of Dechra Pharmaceuticals plc in a research report on Sunday, September 11th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 1,333.86 ($16.55).

Dechra Pharmaceuticals plc Company Profile

Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world. The Company’s segments include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American (NA) Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development.

Receive News & Stock Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related stocks with our FREE daily email newsletter.